These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8983927)

  • 1. Prevention and management of thrombotic complications during coronary interventions. Proceedings of a conference. Sophia Antipolis, France, 16-18 February 1995.
    Eur Heart J; 1995 Nov; 16 Suppl L():1-107. PubMed ID: 8983927
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombosis in congenital heart disease.
    Khairy P
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1579-82. PubMed ID: 24215186
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
    Sabatier B; Trinquart L; Emmerich J
    Arch Cardiovasc Dis; 2010 Oct; 103(10):497-501. PubMed ID: 21130962
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):100-12. PubMed ID: 20926950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy for the reduction of stent thrombosis.
    Yang DC; Swaminathan RV; Kim LK; Feldman DN
    Expert Rev Cardiovasc Ther; 2013 May; 11(5):567-76. PubMed ID: 23621139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based management of patients undergoing PCI: stent controversies.
    Vetrovec GW
    Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S39-42. PubMed ID: 20333706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The score is in but is the decision final?
    Brinker J
    J Am Coll Cardiol; 2010 Jun; 55(23):2567-9. PubMed ID: 20513596
    [No Abstract]   [Full Text] [Related]  

  • 9. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.
    Garg R; Uretsky BF; Lev EI
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):388-406. PubMed ID: 17722043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Do all the patients with adult-onset diabetes mellitus need acetylsalicylic acid?].
    Lassila R
    Duodecim; 1999; 115(10):1174-7. PubMed ID: 11877857
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of thrombosis and its prevention.
    Lowe GD
    Br J Clin Pharmacol; 2002 Jul; 54(1):96-100. PubMed ID: 12100233
    [No Abstract]   [Full Text] [Related]  

  • 13. Diminishing impact of in-lab complications.
    Tommaso CL; Bergelson BA
    Cathet Cardiovasc Diagn; 1997 Nov; 42(3):257-8. PubMed ID: 9367095
    [No Abstract]   [Full Text] [Related]  

  • 14. Coronary thrombosis in diabetes: Are we doing enough?
    Ajjan RA
    Diab Vasc Dis Res; 2016 Nov; 13(6):445-448. PubMed ID: 27555606
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update.
    Cuisset T; Valgimigli M; Mudra H; Muller O; Wijns W; Huber K
    EuroIntervention; 2010 May; 6(1):39-45. PubMed ID: 20542796
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions.
    Cuisset T; Mudra H; Muller O; Vogt P; Angelillo-Scherrer A; Huber K
    EuroIntervention; 2008 Aug; 4(2):183-6. PubMed ID: 19110780
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombosis in continuous-flow left ventricular assist devices: pathophysiology, prevention, and pharmacologic management.
    Jennings DL; Weeks PA
    Pharmacotherapy; 2015 Jan; 35(1):79-98. PubMed ID: 25329333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic disorders.
    Collins P; Kelsey H
    J R Coll Physicians Lond; 1996; 30(4):381-5. PubMed ID: 8875387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Platelet function inhibitors as a way of arterial thrombosis prevention in the diabetic].
    Lecompte T
    Journ Annu Diabetol Hotel Dieu; 2001; ():197-220. PubMed ID: 11565463
    [No Abstract]   [Full Text] [Related]  

  • 20. Antithrombotic management with a stable prostacyclin analogue during extracorporeal circulation.
    Maurin N
    Contrib Nephrol; 1991; 93():205-9. PubMed ID: 1802582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.